Ocular Therapeutix, Inc. OCUL

Company Overview

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of ophthalmic therapies using its proprietary hydrogel-based drug delivery technology. The company operates within the ophthalmology and biotechnology industries, targeting chronic and post-surgical eye diseases where sustained drug delivery can improve efficacy, adherence, and patient outcomes. Its core approach is the use of bioresorbable, extended-release formulations designed to deliver therapeutics to ocular tissues over weeks to months.

The company’s primary revenue drivers are currently tied to product sales and collaboration-related income, with longer-term value centered on its clinical-stage pipeline. Ocular Therapeutix was founded in 2006 and completed its initial public offering in 2014. Initially focused on post-surgical ophthalmic applications, the company has since evolved its strategy toward chronic retinal and ocular surface diseases, repositioning its pipeline toward larger, longer-duration commercial opportunities.